desk
Share
News Topical, Digital Desk : Pharma sector giant Sun Pharma has presented its quarterly results. The company's consolidated profit has fallen by 20 percent compared to last year, while the figures have been weaker than market estimates. At the same time, the company's income has increased by 10 percent on a year-on-year basis. This has been better than the estimate. Despite the increase in income, the main reason for the fall in profit is the company's one-time loss of Rs 818 crore, which affected the profit. There is pressure on the stock after the results. The stock registered a rise after the results and then came back into the red zone.
How were the quarterly results?
The consolidated profit of the company has come down from Rs 2,836 crore to Rs 2,279 crore, a decline of 19.64 percent compared to last year, this profit figure has been below the market estimates. The market had given an estimate of profit reaching Rs 3,179 crore with an increase. However, the figure has come down due to one-time loss. The consolidated income of the company has increased from Rs 12,653 crore to Rs 13,891 crore and a growth of 9.7 percent has been registered in it. This has been better than the market estimate. The market had estimated the income to be Rs 13,421 crore. At the same time, EBITDA has increased by 19.2 percent compared to last year and has reached Rs 4,302 crore from Rs 3,608 crore. The market had given an estimate of EBITDA of Rs 3,687 crore. At the same time, the company's EBITDA margin has increased on a year-on-year basis and has increased from 28.5% to 31.1%.
--Advertisement--
